Sign in
HUMAW Stock Price, Chart, Stats & News
Humacyte, Inc.
Save
Humacyte, Inc. (HUMAW) does not currently pay a dividend.
1.08M
Market cap
–
Current P/E
–
Forward P/E
HUMAW chart
Fundamentals
Gross margin | -134.49% |
Operating margin | -5306.04% |
Pretax margin | -786.51% |
Net margin | -2003.58% |
Effective tax rate | – |
ROA | -35.09% |
ROE | -424.76% |
D/E | 20.86x |
Interest coverage ratio | -21.64x |
HUMAW valuation
P/E | – |
P/S | 51.97x |
P/B | 34.37x |
P/CF | -1.02x |
P/FCF | -1.00x |
P/OCF | -1.02x |
PEG | -0.60x |
EV multiple | -2.76x |
About
Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas. The company employs its distinct, proprietary scientific platform to engineer and manufacture human acellular vessels (HAVs).
Similar securities
Based on sector and market capitalization
Report issue